Synta Pharmaceuticals's Lung Cancer Drug Struggles to Remain Relevant

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The efficacy of Synta Pharmaceuticals' (SNTA_) lung cancer drug ganetespib is weakening over time, which should raise even more concerns about the ongoing phase III clinical trial.

Snyta shares are down 17% to $6.15 in early Monday trading.

The latest update from the phase II "Galaxy-1" study, which compares ganetespib plus docetaxel against docetaxel alone in second-line non-small cell lung cancer, are being presented Monday during the American Society of Clinical Oncology (ASCO) annual meeting:

Help employers find you! Check out all the jobs and post your resume.

Back to news